279 related articles for article (PubMed ID: 36995469)
1. Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.
Kavanaugh A; Baraliakos X; Gao S; Chen W; Sweet K; Chakravarty SD; Song Q; Shawi M; Rahman P
Adv Ther; 2023 May; 40(5):2439-2456. PubMed ID: 36995469
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of possible HLA biomarkers in axial spondyloarthritis beyond HLA-B27 positivity.
Šegota A; Schnurrer-Luke-Vrbanić T; Avancini-Dobrović V; Mirić F
Rheumatol Int; 2023 Nov; 43(11):2073-2079. PubMed ID: 37450032
[TBL] [Abstract][Full Text] [Related]
3. Disease characteristics, pathogenesis, and treatment controversies of axial psoriatic arthritis.
Yousif P; Nahra V; Khan MA; Magrey M
Joint Bone Spine; 2024 Jan; 91(1):105625. PubMed ID: 37495073
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Xu S; Quinn ST; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar A; Østergaard M; Baraliakos X
Trials; 2022 Sep; 23(1):743. PubMed ID: 36064592
[TBL] [Abstract][Full Text] [Related]
5. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA.
Regierer AC; Weiß A; Proft F; Baraliakos X; Behrens F; Poddubnyy D; Schett G; Lorenz HM; Worsch M; Strangfeld A
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36898762
[TBL] [Abstract][Full Text] [Related]
6. Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study.
Benavent D; Plasencia C; Poddubnyy D; Kishimoto M; Proft F; Sawada H; López-Medina C; Dougados M; Navarro-Compán V
Semin Arthritis Rheum; 2021 Aug; 51(4):766-774. PubMed ID: 34144387
[TBL] [Abstract][Full Text] [Related]
7. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
Braun J; Landewé RB
Ann Rheum Dis; 2022 Apr; 81(4):466-468. PubMed ID: 34656991
[TBL] [Abstract][Full Text] [Related]
8. Axial spondyloarthritis and axial psoriatic arthritis: similar or different disease spectrum?
Benavent D; Plasencia-Rodríguez C; Franco-Gómez K; Nieto R; Monjo-Henry I; Peiteado D; Balsa A; Navarro-Compán V
Ther Adv Musculoskelet Dis; 2020; 12():1759720X20971889. PubMed ID: 33240404
[TBL] [Abstract][Full Text] [Related]
9. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials.
Sweet K; Song Q; Loza MJ; McInnes IB; Ma K; Leander K; Lakshminarayanan V; Franks C; Cooper P; Siebert S
RMD Open; 2021 May; 7(2):. PubMed ID: 34011674
[TBL] [Abstract][Full Text] [Related]
11. Axial Disease in Psoriatic Arthritis: how can we Define it, and does it have an Impact on Treatment?
Lopez-Medina C; Ziade N
Mediterr J Rheumatol; 2022 Mar; 33(Suppl 1):142-149. PubMed ID: 36127925
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies.
Mease PJ; Helliwell PS; Gladman DD; Poddubnyy D; Baraliakos X; Chakravarty SD; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Sweet K; Shawi M; Karyekar CS; Deodhar A; van der Heijde D
Lancet Rheumatol; 2021 Oct; 3(10):e715-e723. PubMed ID: 38287608
[TBL] [Abstract][Full Text] [Related]
13. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
[TBL] [Abstract][Full Text] [Related]
14. IL-23 and axial disease: do they come together?
Mease P; van den Bosch F
Rheumatology (Oxford); 2021 Oct; 60(Suppl 4):iv28-iv33. PubMed ID: 34668015
[TBL] [Abstract][Full Text] [Related]
15. Psoriatic Spondylitis: A Disease Manifestation in Debate: Evidences to Know for the Clinical Rheumatologist.
Zeidler HK
J Clin Rheumatol; 2022 Jan; 28(1):38-43. PubMed ID: 34941618
[TBL] [Abstract][Full Text] [Related]
16. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
Rahman P; Mease PJ; Helliwell PS; Deodhar A; Gossec L; Kavanaugh A; Kollmeier AP; Hsia EC; Zhou B; Lin X; Shawi M; Karyekar CS; Han C
Arthritis Res Ther; 2021 Jul; 23(1):190. PubMed ID: 34261541
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry.
Ciurea A; Götschi A; Kissling S; Bernatschek A; Bürki K; Exer P; Nissen MJ; Möller B; Scherer A; Micheroli R
RMD Open; 2023 Jun; 9(2):. PubMed ID: 37277211
[TBL] [Abstract][Full Text] [Related]
18. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
[TBL] [Abstract][Full Text] [Related]
19. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
[TBL] [Abstract][Full Text] [Related]
20. Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis.
Jadon DR; Sengupta R; Nightingale A; Lindsay M; Korendowych E; Robinson G; Jobling A; Shaddick G; Bi J; Winchester R; Giles JT; McHugh NJ
Ann Rheum Dis; 2017 Apr; 76(4):701-707. PubMed ID: 27913376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
